Development And Evaluation Of Gastroretentive Floating Tablet Of Rosuvastatin
Volume 1 - Issue 2, August 2017 Edition
[Download Full Paper]
Amiya kumar Prusty, Archana P. Chand
Gastroretentive dosage form, antihyperlipidemic drug, Rosuvastatin, Mucoadhesion.
Gastroretentive floating matrix tablets of the antihyperlipidemic drug Rosuvastatin were successfully prepared using hydrophilic polymers like HPMC K4M and Carbapol. From the Preformulation studies for drug excipients compatibility it was observed that there was no compatibility problem with the excipients used in the study. The Formulated tablets gave satisfactory results for various physicochemical evaluation studies like Weight variation, Floating lag time, Content uniformity, Total floating time, Mucoadhesion time, mucoadhesive strength and in vitro drug release and shows a floating time of around 12 hrs.
. G Ponchel, J M Irache. â€œSpecific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tractâ€, Advanced Drug Del Review, pp.191-219, 1998.
. A Deshpande, N H Shah, C T Rhodes, W Malick. â€œevelopment of a novel controlledreleasesystem for gastric retentionâ€, Pharm Research,pp. 815-819,1997.
. S S Davis, A F Stockwell, M J Taylor. â€œThe effect of density on the gastricemptying of single and multiple unit dosage formsâ€, Pharm Research, pp.208-213,1986.
. J Urguhart, F Theeuwes, â€œDrug delivery system comprising a reservoircontaining a plurality of tiny pillsâ€ US patent 4 434 153. February 28, 1994.
. J A Fix, R Cargill, K Engle. â€œControlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteersâ€, Pharm Research, pp. 1087-1089,1993.
. R Groning, G Heun. â€œOral dosage forms with controlled gastrointestinal transitâ€, Drug Dev Ind Pharm, pp.527-539 (1984).
. R Groning, G Heun. â€œDosage forms with controlled gastrointestinal passageâ€”studies on the absorption of nitrofurantoinâ€, Int J Pharm, pp.111-116,1989.
. W Wu, Q Zhou, H B Zhang, G D Ma, C D Fu. â€œStudies on nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident timeâ€, Yao Xue Xue Bao, pp.86-790, 1997.
. G G Holz and O G Chepurny. â€œGlucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitusâ€, Curr. Med. Chem. pp. 2471-2483,2003.
. S Li, S Lin, B.P Daggy, H L Mirchandani, Y W Chien. â€œEffect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial designâ€, Int. J. Pharm, pp.13-22, 2003.
. R N Panigrahy, A M Mahale, D M Sakarkar. â€œDesign development and in vitro testing of a combined bioadhesive-floating oral drug delivery systemâ€, Journal of Pharmacy Research, pp. 212-2215, 2011.
. Y Zhang, M Huo, J Zhou, A Zou, W Li. â€œDDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profilesâ€, The AAPS Journal pp. 12, 2010.
. W I Higuchi. â€œDiffusional models useful in biopharmaceutics-drug release rate processesâ€ J Pharm Sci, pp.315-24, 1967.
. N A Peppas, P L Ritger. â€œA simple equation for description of solute release II. Fickian and anomalous release from swellable devicesâ€ J Control Release, pp.37-42, 1987.